glp-1 drugs retatrutide Unapproved weight loss drug causes extreme side effects Retatrutide vs. Tirzepatide: The Next-Gen

I'm pleased to share that npj Metabolic Health and Disease is joining Communications Medicine on a new collection looking at the Therapeutic Landscape of GLP1 agonists.

We have reviewed the metabolic effects of these drugs in relation to improvement of diabetic hyperglycaemia and fatty liver disease, as well as peripheral metabolism and insulin resistance

These findings support their use as a valuable adjunctive obesity management medication (OMMs) in post-bariatric care, though long-term adherence and cost-effectiveness require further investigation

Humana blocks Wegovy for weight loss using automated diagnosis code editsnot PA denials

Use of blockbuster anti-obesity drugs like Wegovy and Zepbound is growing, with about 1 in 8 adults in the U.S